What is Progyny?
Fertility, family-building, and women's health benefits company with $328.5M Q1 2026 revenue; 2025 revenue outlook exceeded $1.26B scale.
- Category
- Fertility, family-building, and women's health benefits
- Headquarters
- New York, NY
- Founded
- 2008
- Employees
- 700+
- Total funding
- Public company; not venture-round led
- Status
- Nasdaq: PGNY
What is Progyny?
Progyny is a Fertility, family-building, and women's health benefits company headquartered in New York, NY. As of June 2026, its clearest scale signal is $328.5M Q1 2026 revenue; 2025 revenue outlook exceeded $1.26B.
Progyny operates a fertility and family-building benefits manager with clinic-network, pharmacy, care-navigation, and employer-benefit products. Its core customer set includes large employers, health plans, members, fertility clinics, pharmacy partners, and benefits consultants, and its public product surface includes Fertility benefits, Progyny Rx, Menopause and women's health support, Preconception and pregnancy support, Provider network. The current scale signal is $328.5M Q1 2026 revenue; 2025 revenue outlook exceeded $1.26B, which makes this a mid-market public account with real enterprise procurement capacity rather than an early-stage startup.
The company competes where healthcare buyers care about evidence, reliability, compliance, integrations, and measurable operational or clinical outcomes. Vendor evaluation usually involves business owners plus finance, security, legal, procurement, data, clinical, quality, compliance, and IT stakeholders.
For sellers, the account should be approached as a public-company buying center. The strongest angles connect directly to growth, retention, margin expansion, reimbursement, quality, member or patient experience, regulated data handling, workflow automation, or lower cost to serve.
What does Progyny offer?
Progyny offers Fertility benefits, Progyny Rx, Menopause and women's health support, Preconception and pregnancy support and related healthcare workflows.
- Fertility benefits· Core product
- Progyny Rx· Core product
- Menopause and women's health support· Core product
- Preconception and pregnancy support· Workflow
- Provider network· Workflow
- Member care advocates· Workflow
- Analytics· Platform
- Global fertility benefits· Platform
How does Progyny make money?
Progyny earns revenue from employer-sponsored fertility and family-building benefits, pharmacy services, and related care-navigation programs.
Progyny earns revenue from employer-sponsored fertility and family-building benefits, pharmacy services, and related care-navigation programs. Growth is driven by the same operating levers buyers track internally: customer volume, recurring revenue, utilization, reimbursement, renewal rates, attach rates, product expansion, and disciplined cost control.
Contracts are employer-specific and commonly priced through PEPM administration, bundled smart-cycle benefit design, pharmacy economics, network terms, and utilization guarantees rather than public tiers. In practice, commercial packaging usually separates strategic enterprise accounts, standard commercial customers, implementation services, support, usage, and renewal economics.
For a seller, budget access depends on showing a near-term connection to revenue capture, margin improvement, compliance, uptime, provider or member experience, data quality, clinical evidence, or workflow throughput. Generic efficiency claims are weaker than quantified impact on one of those operating levers.
Who leads Progyny?
Progyny is led by Pete Anevski, with finance, product, clinical, technology, commercial, and operations leaders influencing major vendor decisions.
- Pete AnevskiChief Executive OfficerCEO since 2023Leads employer-benefits growth and operating execution.
- David SchlangerExecutive ChairmanExecutive chairmanFormer CEO and board leader.
- Mark LivingstonChief Financial OfficerCFOOwns finance and investor communications.
- Georgia WitkinChief Medical OfficerClinical leaderGuides clinical and member support programs.
How do you contact Progyny's leadership?
Progyny publishes an official investor-relations or corporate contact route, but this profile does not present guessed personal executive emails as verified. Use the official contact listed here, the company contact page, or a relationship-based introduction for executive outreach.
investors@progyny.com (official published/company IR contact); personal executive format not verifiedHow much funding has Progyny raised?
Progyny is a public company (Nasdaq: PGNY), so the current capital story is public-market status, operating cash flow, debt or equity access, and acquisitions rather than a private startup round stack.
2008: Founded - Progyny's predecessor fertility-benefit platform is formed. 2019: IPO - Progyny lists on Nasdaq under PGNY. 2023: CEO transition - Pete Anevski becomes CEO. 2025: Record revenue year - Progyny reports a record 2025 with revenue projected above $1.26B during the year. 2026: Q1 2026 results - Progyny reports $328.5M of Q1 revenue.
As of June 2026, Progyny's practical funding capacity is best read through Nasdaq: PGNY, $328.5M Q1 2026 revenue; 2025 revenue outlook exceeded $1.26B, its latest annual or quarterly filings, cash flow, balance sheet, and guidance. For public mid-market healthcare companies, the next budget cycle is usually governed by operating plans and investor commitments, not by a new venture round.
Seller signal: public-company status gives Progyny access to mature procurement and repeat budget cycles, but it also raises the proof bar. Successful pitches need a measurable business case, clean implementation plan, security and compliance readiness, and executive sponsorship from the functional owner.
How did Progyny get here?
Progyny grew through founding, product expansion, public-market milestones, and its latest June 2026 operating update.
- 2008Company foundedProgyny begins building managed fertility-benefit products.
- 2016Smart Cycle model scalesThe benefit design becomes central to employer adoption.
- 2019Public listingProgyny lists on Nasdaq.
- 2023Leadership transitionPete Anevski takes the CEO role.
- 2025Employer expansionRevenue grows despite transition of a large client.
- 2026Q1 record revenueProgyny reports $328.5M of Q1 2026 revenue.
Who are Progyny's competitors?
Progyny competes with public companies, private healthcare platforms, software vendors, services firms, and specialized workflow providers depending on the buyer's problem.
- Maven ClinicVirtual clinic for fertility, pregnancy, parenting, and women's health.
- Carrot FertilityGlobal fertility and family-forming benefits platform.
- WINFertilityFertility-management and reproductive-health benefit competitor.
- KindbodyFertility clinic network and employer-benefits competitor.
- Ovia HealthWomen's and family-health digital support platform.
- Included HealthNavigation and specialty-care platform that can overlap in benefits buying committees.
Progyny — frequently asked questions
